Pfizer and Sidekick Health Launches Digital Therapeutics Solution for Eczema

What You Should Know:

– Sidekick Health today announces the launch of an integrated digital therapeutics solution for improving the outcomes of patients with Atopic Dermatitis (AD) in conjunction with Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies.

– Sidekick and Pfizer will be rolling out their integrated digital therapeutics offering, launching first in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later in 2022. This marks the next phase of a growing relationship to develop digital patient support programs globally, including expansion into 24 markets by 2024.

Challenges Treating AD

AD is an inflammatory, pruritic, chronic, or chronically relapsing skin disease that affects up to 14% of adults worldwide. People living with moderate to severe AD often have to deal with constant and relentless itching, leading to sleep deprivation, increased stress and anxiety that affects the quality of their lives.

One of the challenges of effectively treating AD is that patients’ adherence to treatment tends to be low. Sidekick’s DTx platform addresses this using gamification principles, behavioral economics, and artificial intelligence (AI) to deliver treatment through dynamic care pathways that help inspire lasting behavioral change, positively impacting health outcomes.

Clinical Outcomes/Results

Research has shown that treatment adherence is low when it comes to AD. In a feasibility study, Sidekick has proven to improve medication adherence in 83% of patients using the app to manage their chronic illnesses. Additionally, AD sufferers often self-administer using a range of different treatments coupled with inconsistent application routines that undermine adherence.

“We are extremely excited to be entering the next phase in our ongoing relationship with Pfizer,” comments Dr. Tryggvi Thorgeirsson, CEO and Co-Founder of Sidekick. “At Sidekick, it’s always been our ambition to help as many people as possible to make long-lasting improvements to their disease management, with the aim of improving people’s health outcomes and quality of life. Our work with Pfizer escalates our mission to bring digital therapeutics into the homes of people around the world